Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 2 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 33 of 33

TitleReference numberPublishedLast updated
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)TA700
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Panobinostat for treating multiple myeloma after at least 2 previous treatmentsTA380
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Bortezomib and thalidomide for the first‑line treatment of multiple myelomaTA228
Bortezomib monotherapy for relapsed multiple myelomaTA129

Results per page

  1. 10
  2. 25
  3. 50
  4. All